{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:29:47Z","timestamp":1784071787802,"version":"3.55.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Clinical inertia, or therapeutic inertia (TI), is the medical behaviour of not initiating or intensifying treatment when recommended by clinical recommendations. To our knowledge, our survey is the first to assess TI around psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Eight hundred and twenty-five French rheumatologists were contacted via email between January and March 2021 and invited to complete an online questionnaire consisting of seven clinical vignettes: five cases (\u2018oligoarthritis\u2019, \u2018enthesitis\u2019, \u2018polyarthritis\u2019, \u2018neoplastic history\u2019, \u2018cardiovascular risk\u2019) requiring treatment OPTImization, and two \u2018control\u2019 cases (distal interphalangeal arthritis, atypical axial involvement) not requiring any change of treatment\u2014according to the most recent PsA recommendations. Rheumatologists were also questioned about their routine practice, continuing medical education and perception of PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and one rheumatologists completed this OPTI\u2019PsA survey. Almost half the respondents (47%) demonstrated TI on at least one of the five vignettes that warranted treatment optimization. The complex profiles inducing the most TI were \u2018oligoarthritis\u2019 and \u2018enthesitis\u2019 with 20% and 19% of respondents not modifying treatment, respectively. Conversely, clinical profiles for which there was the least uncertainty (\u2018polyarthritis in relapse\u2019, \u2018neoplastic history\u2019 and \u2018cardiovascular risk\u2019) generated less TI with 11%, 8% and 6% of respondents, respectively, choosing not to change the current treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rate of TI we observed for PsA is similar to published data for other chronic diseases such as diabetes, hypertension, gout or multiple sclerosis. Our study is the first to show marked clinical inertia in PsA, and further research is warranted to ascertain the reasons behind this inertia.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/kead262","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T03:49:06Z","timestamp":1685591346000},"page":"516-524","source":"Crossref","is-referenced-by-count":4,"title":["A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI\u2019PsA)"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-0726","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, UFR de M\u00e9decine , Paris, France"},{"name":"Rheumatology Department & INSERM U1132 Bioscar, Viggo Petersen Centre, Lariboisi\u00e8re Hospital , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Pierre-Paul Riquet Hospital , Toulouse, France"},{"name":"Universit\u00e9 Toulouse III\u2014Paul Sabatier & INSERM, 1291 Infinity , Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Dahan","sequence":"additional","affiliation":[{"name":"Rheumatology Department, UF 6501, Hautepierre Hospital , CHU Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Quiniou","sequence":"additional","affiliation":[{"name":"Amgen , Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Frazier","sequence":"additional","affiliation":[{"name":"Rheumatology Department & INSERM U1132 Bioscar, Viggo Petersen Centre, Lariboisi\u00e8re Hospital , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, National Reference Centre for Rare Systemic Auto-immune Diseases East-South-West (RESO) , CHU Strasbourg, France"},{"name":"Molecular Immuno-Rhumatology Laboratory, GENOMAX platform, INSERM UMR-S1109, Faculty of Medicine, Interdisciplinary Thematic Institute (ITI) of Precision Medicine of Strasbourg, Transplantex NG, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg , Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2024020223065399100_kead262-B1","first-page":"243","article-title":"\u00c9pid\u00e9miologie du rhumatisme psoriasique","volume":"6773","author":"Lukas","year":"2020","journal-title":"Rev Rhum Monogr"},{"key":"2024020223065399100_kead262-B2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","article-title":"Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database","volume":"60","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology"},{"key":"2024020223065399100_kead262-B3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"2024020223065399100_kead262-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024020223065399100_kead262-B5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024020223065399100_kead262-B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024020223065399100_kead262-B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel concepts in psoriatic arthritis management: can we treat to target?","volume":"20","author":"Tucker","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2024020223065399100_kead262-B8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.181472","article-title":"Treating psoriatic arthritis to target: defining the psoriatic arthritis disease activity score that reflects a state of minimal disease activity","volume":"47","author":"Perruccio","year":"2020","journal-title":"J Rheumatol"},{"key":"2024020223065399100_kead262-B9","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2024020223065399100_kead262-B10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"2024020223065399100_kead262-B11","doi-asserted-by":"crossref","first-page":"e001083","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in PsA: methods and necessity","volume":"6","author":"Dures","year":"2020","journal-title":"RMD Open"},{"key":"2024020223065399100_kead262-B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","article-title":"US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey","volume":"17","author":"Lebwohl","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2024020223065399100_kead262-B13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"2024020223065399100_kead262-B14","volume-title":"Advances in patient safety: from research to implemtation. Vol. 2: concepts and methodology","author":"O\u2019Connor","year":"2005"},{"key":"2024020223065399100_kead262-B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","article-title":"Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals","volume":"47","author":"Okonofua","year":"2006","journal-title":"Hypertension"},{"key":"2024020223065399100_kead262-B16","doi-asserted-by":"crossref","first-page":"383; author reply 383","DOI":"10.1001\/jama.2011.1044","article-title":"Clinical inertia and uncertainty in medicine","volume":"306","author":"Mohan","year":"2011","journal-title":"JAMA"},{"key":"2024020223065399100_kead262-B17","first-page":"232","article-title":"Inertia in clinical practice: causes, consequences, solutions","volume":"65","author":"Scheen","year":"2010","journal-title":"Rev Med Liege"},{"key":"2024020223065399100_kead262-B18","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S1262-3636(12)71534-3","article-title":"Therapeutic inertia in type 2 diabetes: insights from the PANORAMA study in France","volume":"38(Suppl 3)","author":"Simon","year":"2012","journal-title":"Diabetes Metab"},{"key":"2024020223065399100_kead262-B19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12883-016-0577-4","article-title":"Decision making under uncertainty, therapeutic inertia, and physicians\u2019 risk preferences in the management of multiple sclerosis (DIScUTIR MS)","volume":"16","author":"Saposnik","year":"2016","journal-title":"BMC Neurol"},{"key":"2024020223065399100_kead262-B20","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2296-15-130","article-title":"The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review","volume":"15","author":"Lebeau","year":"2014","journal-title":"BMC Fam Pract"},{"key":"2024020223065399100_kead262-B21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing clinical inertia in type 2 diabetes mellitus: a review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv Ther"},{"key":"2024020223065399100_kead262-B22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1464-5491.2004.01095.x","article-title":"Clinical inertia in the management of Type 2 diabetes metabolic risk factors","volume":"21","author":"Grant","year":"2004","journal-title":"Diabet Med"},{"key":"2024020223065399100_kead262-B23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2024020223065399100_kead262-B24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJM199812313392701","article-title":"Inadequate management of blood pressure in a hypertensive population","volume":"339","author":"Berlowitz","year":"1998","journal-title":"N Engl J Med"},{"key":"2024020223065399100_kead262-B25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037050903350762","article-title":"Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors","volume":"19","author":"Gil-Guill\u00e9n","year":"2010","journal-title":"Blood Press"},{"key":"2024020223065399100_kead262-B26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fneur.2018.00781","article-title":"Therapeutic inertia in multiple sclerosis care: a study of canadian neurologists","volume":"9","author":"Saposnik","year":"2018","journal-title":"Front Neurol"},{"key":"2024020223065399100_kead262-B27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fneur.2018.00174","article-title":"Therapeutic inertia in the new landscape of multiple sclerosis care","volume":"9","author":"Saposnik","year":"2018","journal-title":"Front Neurol"},{"key":"2024020223065399100_kead262-B28","doi-asserted-by":"crossref","first-page":"e197093","DOI":"10.1001\/jamanetworkopen.2019.7093","article-title":"Comparison of physician therapeutic inertia for management of patients with multiple sclerosis in Canada, Argentina, Chile, and Spain","volume":"2","author":"Almusalam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2024020223065399100_kead262-B29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jbspin.2017.04.002","article-title":"GOSPEL 3: management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century \u2013 comparison with 2006 EULAR recommendations","volume":"84","author":"Goossens","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2024020223065399100_kead262-B30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: an observational French longitudinal patient database study","volume":"85","author":"Maravic","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2024020223065399100_kead262-B31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40744-017-0091-1","article-title":"Improvement in diagnosis and treat-to-target management of hyperuricemia in gout: results from the GEMA-2 transversal study on practice","volume":"5","author":"Perez Ruiz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2024020223065399100_kead262-B32","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/jdv.15882","article-title":"Therapeutic inertia in the management of moderate-to-severe plaque psoriasis","volume":"34","author":"Halioua","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024020223065399100_kead262-B33","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/ijd.14914","article-title":"Perception of therapeutic inertia by patients with psoriasis in France","volume":"59","author":"Halioua","year":"2020","journal-title":"Int J Dermatol"},{"key":"2024020223065399100_kead262-B34","doi-asserted-by":"crossref","first-page":"adv00475","DOI":"10.2340\/00015555-3813","article-title":"Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents","volume":"101","author":"Melin","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024020223065399100_kead262-B35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1472-6963-9-128","article-title":"Effect of response format for clinical vignettes on reporting quality of physician practice","volume":"9","author":"Pham","year":"2009","journal-title":"BMC Health Serv Res"},{"key":"2024020223065399100_kead262-B36","doi-asserted-by":"crossref","first-page":"2381468319855642","DOI":"10.1177\/2381468319855642","article-title":"Traffic lights intervention reduces therapeutic inertia: a randomized controlled trial in multiple sclerosis care","volume":"4","author":"Saposnik","year":"2019","journal-title":"MDM Policy Pract"},{"key":"2024020223065399100_kead262-B37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024020223065399100_kead262-B38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jbspin.2018.01.006","article-title":"2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2024020223065399100_kead262-B39","author":"DREES"},{"key":"2024020223065399100_kead262-B40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2337\/diacare.28.3.600","article-title":"Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?","volume":"28","author":"Shah","year":"2005","journal-title":"Diabetes Care"},{"key":"2024020223065399100_kead262-B41","doi-asserted-by":"crossref","first-page":"e736\u201343","DOI":"10.1016\/S2214-109X(18)30259-6","article-title":"May Measurement Month 2017: an analysis of blood pressure screening results worldwide","volume":"6","author":"Beaney","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2024020223065399100_kead262-B42","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/jcm10235659","article-title":"Implementation of the treat-to-target concept in evaluation of psoriatic arthritis patients","volume":"10","author":"Gazitt","year":"2021","journal-title":"J Clin Med"},{"key":"2024020223065399100_kead262-B43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024020223065399100_kead262-B44","doi-asserted-by":"crossref","first-page":"e000221","DOI":"10.1136\/rmdopen-2015-000221","article-title":"When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)","volume":"2","author":"Gvozdenovi\u0107","year":"2016","journal-title":"RMD Open"},{"key":"2024020223065399100_kead262-B45","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.5114\/aoms.2019.84092","article-title":"Management of rheumatoid arthritis in Poland \u2013 where daily practice might not always meet evidence-based guidelines","volume":"17","author":"Batko","year":"2021","journal-title":"Arch Med Sci"},{"key":"2024020223065399100_kead262-B46","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.283.13.1715","article-title":"Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality","volume":"283","author":"Peabody","year":"2000","journal-title":"JAMA"},{"key":"2024020223065399100_kead262-B47","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.jaut.2019.102398","article-title":"Treat to target in axial spondyloarthritis: from its concept to its implementation","volume":"110","author":"Dougados","year":"2020","journal-title":"J Autoimmun"},{"key":"2024020223065399100_kead262-B48","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/annrheumdis-2015-208617","article-title":"Treating to target in psoriatic arthritis: how to implement in clinical practice","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead262\/50647307\/kead262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/2\/516\/56554071\/kead262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/2\/516\/56554071\/kead262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:24:36Z","timestamp":1729527876000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/2\/516\/7188087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead262","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,6,1]]}}}